

**MTN 037 - A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel)
Administered Rectally to HIV-1 Seronegative Adults
Data as of December 5, 2022**

Accrual Summary by Site

Site	Activation Date	First Enrollment Date	Last Enrollment Date ¹	Duration of Accrual ² (Weeks)	Total Screened	Total Enrolled	Enrollment Target	Screen/Enroll	Average Enrolled per Week	Percent Enrolled	Percent Accrual Duration ³	Final Percent Accrual Duration ⁴
Pittsburgh	26JUN2018	20AUG2018	08JAN2019	20.3	7	6	6	1.2	0.3	100.0%	Completed	63.2%
Birmingham	19JUN2018	06SEP2018	24JAN2019	20.1	9	7	6	1.3	0.3	116.7%	Completed	68.0%
All Sites	19JUN2018	20AUG2018	24JAN2019	224.1	16	13	12	1.2	0.1	108.3%	N/A	N/A

¹ Date of most recent enrollment as of December 5, 2022.

² Duration of accrual based on first enrollment date.

³ This is the percent of time that has elapsed from the first enrollment to the expected duration of accrual per protocol. For example, if the report is run on May 31, 2014, the site's first enrollment is on January 1, 2014 and the expected duration of accrual is 6 months, then the Percent Accrual Duration = 83.3%.

⁴ The percentage of the expected duration of accrual that it took to reach the target accrual. For example, if the report site finished accrual in 3 months but the expected accrual duration was 6 months then Final Percent Accrual Duration is 50%.